Results 111 to 120 of about 8,771 (219)

Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study [PDF]

This study evaluates upadacitinib (UPA) effectiveness and drug retention rate (DRR) in patients with rheumatoid arthritis (RA). Multicentre prospective observational study. Consecutive patients with RA receiving UPA were evaluated at 0, 3, 6, 12, 18, and
Baldi, Caterina, Benucci, Maurizio, Cazzato, Massimiliano, D'Ignazio, Emilio, De Lorenzo, Chiara, Delle Sedie, Andrea, Di Cato, Luca, Di Matteo, Andrea, Frediani, Bruno, Gaggiano, Carla, Gentileschi, Stefano, Guiducci, Serena, Lepri, Gemma, Li Gobbi, Francesca, Nannini, Carlotta, Niccoli, Laura, Panaccione, Anna, Picchianti-Diamanti, Andrea   +17 more
core   +1 more source

Upadacitinib for the treatment of radiographic axial spondyloarthritis — case series and review of the literature

Drugs in Context
Upadacitinib is a Janus kinase (JAK) inhibitor approved for the treatment of different rheumatic diseases, including axial spondyloarthritis (axSpA).
Giuseppe Lopalco, Arianna D’Antonio, Maria Sole Chimenti, Florenzo Iannone   +3 more
doaj   +1 more source

A review on potential adverse effects associated with Janus-kinase inhibitors [PDF]

Rheumatoid arthritis (RA) is a chronic, symmetrical, inflammatory autoimmune disease that affects small joints. RA has a population prevalence of 0.5% to 1% in the U.S. The annual cost of care for chronic treatment of RA in the United States is estimated
Kesavulu, Chennasamudram C., Kumar, Jutla V., P., Yashmeen Nikhat, Pooja, Mydukuru   +3 more
core   +2 more sources

JAK inhibitors and menstrual cycle alterations: insights from a case series of 16 female patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Luciano Ibba, Luigi Gargiulo, Matteo Bianco, Sara Di Giulio, Ruggero Cascio Ingurgio, Angela Alfano, Carlo A. Vignoli, Mario Valenti, Paola Facheris, Chiara Perugini, Alessandra Narcisi, Antonio Costanzo   +11 more
wiley   +1 more source

The role of neutrophils in the pathophysiology of inflammatory bowel diseases

Periodontology 2000, EarlyView.
Abstract Objectives Inflammatory bowel disease (IBD) encompasses a spectrum of chronic disorders of the gastrointestinal tract, with a potential bidirectional relationship with periodontitis. Neutrophils are key regulators of immune‐inflammatory responses and play a major role in both diseases.
Joao Paulo Steffens, Ekin Yay‐Kus, Rafael Scaf de Molon, Viorelia Stoica, Peter Rimmer, Josefine Hirschfeld, Asif Jilani Iqbal, Tariq Iqbal, Iain Chapple   +8 more
wiley   +1 more source

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study

Journal of Dermatological Treatment
Purpose: Atopic dermatitis (AD) adversely impacts quality of life (QoL). We evaluated the effect of upadacitinib, an oral selective Janus kinase inhibitor approved for moderate-to-severe AD, plus topical corticosteroids (+TCS) on patient-reported ...
Nina Magnolo, Michael C. Cameron, Mona Shahriari, Bob Geng, Brian M. Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Yingyi Liu, Shiyu Zhang, Cristina Sancho Sanchez, Katherine Altman, Richard G. Langley   +12 more
doaj   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis

Patient Preference and Adherence
Yan Teng, Yi Tang, Yibin Fan, Xiaohua Tao,* Yang Ding* Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital of Hangzhou Medical College, Hangzhou, People’s ...
Teng Y, Tang Y, Fan Y, Tao X, Ding Y
doaj  

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber, Knut Schäkel, Alexander Enk, Julia K. Winkler   +3 more
wiley   +1 more source

Combination of Upadacitinib and Risankizumab in Refractory Crohn's Disease

JCC Plus, Volume 1, Issue 3, May 2026.
ABSTRACT Background and Aim Dual targeted therapies (DTT) are a promising off‐label approach for the treatment of refractory Crohn's disease (CD). Upadacitinib and risankizumab are approved for the treatment of moderate to severe CD. Our aim was to evaluate the effectiveness and safety of a combination of upadacitinib and risankizumab for refractory CD.
Clara Ramos‐Belinchon, Nikolas Plevris, Ian Arnott, Shahida Din, Jonathan Blackwell, Charlie W. Lees   +5 more
wiley   +1 more source